PONTE VEDRA BEACH, Fla., July 7, 2021—RedDress, a privately held, Israel and U.S. based wound care company, announced today that the ActiGraft® system was named an outstanding selection of the 2021 honorees of Podiatry Today’s 11th annual “Top 10 Innovations in Podiatry”. This annually published article profiles new and emerging advances in foot and ankle surgery, wound care, technology, and medical devices. Podiatry Today is an award-winning, national publication that emphasizes informative clinical features and columns as well as practice management articles.
ActiGraft, an FDA-cleared solution, is the first wound care product that enables healthcare providers to create – in real time – an autologous blood clot using a patient’s own blood. When applied to the wound, ActiGraft acts as a protective covering and supports the body’s natural healing process. A recently published study, “An Observational Pilot Study to Collect Safety and Efficacy Data on Wound Care Using Whole Blood Clot Technology on Hard-to-Heal Wounds”, found ActiGraft to be safe and effective in promoting healing in patients with chronic wounds. Specifically, an average of 65% reduction in patients’ wound size was achieved after four weeks of using ActiGraft and 94% by week 12. Of these patients, 55% were previously treated for over a year, using other advanced wound care technologies without success until the application of the WBC technology. In four of these cases described, ActiGraft helped prevent patients from having to undergo scheduled amputations.
“We’re proud ActiGraft has been selected as one of the top innovations in podiatry this year as it signals increased recognition of ActiGraft’s success to podiatric wound care and treatment” said Alon Kushnir, Founder and CEO of RedDress. “ActiGraft has the potential to dramatically reduce the clinical and financial burden on patients and the healthcare system, offering safe and effective treatment, suitable for a variety of wounds”.
ActiGraft, based on RedDress’ proprietary patented technology, is an FDA-cleared wound care solution that enables health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.
ActiGraft is intended for exuding cutaneous wounds. ActiGraft includes blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.
RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.
Press and Media Inquiries:
Alessandra Lalli, RedDress
Russ Lalli, RedDress
ActiGraft® is a registered trademark of RedDress Ltd.